The Experts below are selected from a list of 4494 Experts worldwide ranked by ideXlab platform
Edmund S Cibas - One of the best experts on this subject based on the ideXlab platform.
-
The role of thyroid fine needle aspiration cytology and the Bethesda System for reporting thyroid
2020Co-Authors: Massimo Bongiovanni, Edmund S Cibas, William C. FaquinAbstract:Thyroid fine needle aspiration (FNA) is among the most commonly performed non-gynaecologic cytologic procedures and the single most effective tool for guiding the initial management of a patient with a thyroid nodule. Its acceptance as a reliable preoperative test relies on its high sensitivity and specificity. The recently developed Bethesda System for Reporting Thyroid Cytopathology, has advanced the field by promoting a standard reporting terminology for thyroid aspirates. In addition, it allows communication with the referring physician to occur in terms that are unambiguous, reproducible, and clinically helpful.
-
Fine-Needle Aspiration of the Thyroid Gland: The 2017 Bethesda System
2020Co-Authors: William C. Faquin, Guido Fadda, Edmund S CibasAbstract:Abstract Fine-needle aspiration (FNA) is an essential test in the evaluation of a patient with a thyroid nodule. The result of the FNA determines, in large part, whether a patient can be followed clinically or referred for surgery. Guidelines have been established for selecting a nodule for aspiration. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has standardized the reporting of thyroid cytopathology and consists of the following six diagnostic categories: nondiagnostic, benign, atypia of undetermined significance/ follicular lesion of undetermined significance (AUS/FLUS), follicular neoplasm, suspicious for malignancy, and malignant.
-
the 2017 Bethesda System for reporting thyroid cytopathology
Thyroid, 2017Co-Authors: Edmund S CibasAbstract:The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) established a standardized, category-based reporting System for thyroid fine-needle aspiration (FNA) specimens. The 2017 revision reaffirms that every thyroid FNA report should begin with one of six diagnostic categories, the names of which remain unchanged since they were first introduced: (i) nondiagnostic or unsatisfactory; (ii) benign; (iii) atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS); (iv) follicular neoplasm or suspicious for a follicular neoplasm; (v) suspicious for malignancy; and (vi) malignant. There is a choice of two different names for some of the categories. A laboratory should choose the one it prefers and use it exclusively for that category. Synonymous terms (e.g., AUS and FLUS) should not be used to denote two distinct interpretations. Each category has an implied cancer risk that ranges from 0% to 3% for the “benign” category to virtually 100% for the “malignant” categ...
-
the role of thyroid fine needle aspiration cytology and the Bethesda System for reporting thyroid cytopathology
Diagnostic Histopathology, 2011Co-Authors: Edmund S Cibas, Massimo Bongiovanni, William C. FaquinAbstract:Abstract Thyroid fine needle aspiration (FNA) is among the most commonly performed non-gynaecologic cytologic procedures and the single most effective tool for guiding the initial management of a patient with a thyroid nodule. Its acceptance as a reliable preoperative test relies on its high sensitivity and specificity. The recently developed Bethesda System for Reporting Thyroid Cytopathology, has advanced the field by promoting a standard reporting terminology for thyroid aspirates. In addition, it allows communication with the referring physician to occur in terms that are unambiguous, reproducible, and clinically helpful.
-
the Bethesda System for reporting thyroid cytopathology
Thyroid, 2009Co-Authors: Edmund S CibasAbstract:OBJECTIVE: To address terminology and other issues related to thyroid fine-needle aspiration (FNA), the National Cancer Institute (NCI) hosted The NCI Thyroid FNA State of the Science Conference. The conclusions regarding terminology and morphologic criteria from the NCI meeting led to the Bethesda Thyroid Atlas Project and form the framework for the Bethesda System for Reporting Thyroid Cytopathology. DESIGN: Participants of the Atlas Project were selected from among the committee members of the NCI FNA State of the Science Conference and other participants at the live conference. The terminology framework was based on a literature search of English language publications dating back to 1995 using PubMed as the search engine; online forum discussions ( http://thyroidfna.cancer.gov/forums/default.aspx ); and formal interdisciplinary discussions held on October 22 and 23, 2007, in Bethesda, MD. MAIN OUTCOME: For clarity of communication, the Bethesda System for Reporting Thyroid Cytopathology recommends that each report begin with one of the six general diagnostic categories. Each of the categories has an implied cancer risk that links it to an appropriate clinical management guideline. CONCLUSIONS: The project participants hope that the adoption of this framework will facilitate communication among cytopathologists, endocrinologists, surgeons, and radiologists; facilitate cytologic-histologic correlation for thyroid diseases; facilitate research into the understanding of thyroid diseases; and allow easy and reliable sharing of data from different laboratories for national and international collaborative studies.
Helen H. Wang - One of the best experts on this subject based on the ideXlab platform.
-
reporting thyroid fna before and after implementation of the Bethesda System one institution s experience
Diagnostic Cytopathology, 2015Co-Authors: Kathriel J. Brister, Remmi Singh, Helen H. WangAbstract:Background The Bethesda System for Reporting Thyroid Cytopathology was published in 2008 and was implemented at Beth Israel Deaconess Medical Center (BIDMC) in June, 2010. Prior to this date, our diagnostic scheme was similar to the Bethesda System, except for the category of “Atypia/Follicular Lesion of Undetermined Significance” (AUS). This study evaluates the impact of the Bethesda System on the rate and the positive predictive value (PPV) of the diagnostic categories at BIDMC. Methods We performed a retrospective review of all thyroid fine-needle aspirations (FNAs) during the time periods January, 2006 to November, 2008 and June, 2010 to July, 2011 and the subsequent thyroidectomy specimens. Results Post-Bethesda System, diagnoses that are equivocal for diverse reasons and which have wide-ranging PPVs are now all grouped into the AUS category, and the proportion of cases that are in the atypical/AUS category rose from 3.7% in the pre-Bethesda period to 12% in the post-Bethesda period. Conclusion The AUS category has a PPV approaching 50% in our lab. This creates uncertainty regarding the appropriate management for this category and may cause unnecessary overuse of molecular testing for cases in the AUS category. Diagn. Cytopathol. 2015;43:28–31. © 2014 Wiley Periodicals, Inc.
-
Reporting thyroid FNA before and after implementation of the Bethesda System—one institution's experience
Diagnostic Cytopathology, 2014Co-Authors: Kathriel J. Brister, Remmi S. Singh, Helen H. WangAbstract:Background The Bethesda System for Reporting Thyroid Cytopathology was published in 2008 and was implemented at Beth Israel Deaconess Medical Center (BIDMC) in June, 2010. Prior to this date, our diagnostic scheme was similar to the Bethesda System, except for the category of “Atypia/Follicular Lesion of Undetermined Significance” (AUS). This study evaluates the impact of the Bethesda System on the rate and the positive predictive value (PPV) of the diagnostic categories at BIDMC. Methods We performed a retrospective review of all thyroid fine-needle aspirations (FNAs) during the time periods January, 2006 to November, 2008 and June, 2010 to July, 2011 and the subsequent thyroidectomy specimens. Results Post-Bethesda System, diagnoses that are equivocal for diverse reasons and which have wide-ranging PPVs are now all grouped into the AUS category, and the proportion of cases that are in the atypical/AUS category rose from 3.7% in the pre-Bethesda period to 12% in the post-Bethesda period. Conclusion The AUS category has a PPV approaching 50% in our lab. This creates uncertainty regarding the appropriate management for this category and may cause unnecessary overuse of molecular testing for cases in the AUS category. Diagn. Cytopathol. 2015;43:28–31. © 2014 Wiley Periodicals, Inc.
-
eliminating the atypia of undetermined significance follicular lesion of undetermined significance category from the Bethesda System for reporting thyroid cytopathology
American Journal of Clinical Pathology, 2011Co-Authors: Remmi S. Singh, Helen H. WangAbstract:The “Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS)” category in the Bethesda System for Reporting Thyroid Cytology is heterogeneous and includes both specimens with borderline cellularity/compromised quality and those with genuine atypia. We have used a reporting scheme that is similar to the Bethesda System but does not include an AUS/FLUS category. We retrospectively reviewed all reports on thyroid FNA and thyroidectomy specimens submitted to the Beth Israel Deaconess Medical Center from January 2006 to December 2008. The positive predictive values for various categories and subcategories in this scheme demonstrate that the AUS/FLUS category can be eliminated to provide information for the most appropriate management of patients with thyroid nodules.
-
Eliminating the "Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance" category from the Bethesda System for Reporting Thyroid Cytopathology.
American Journal of Clinical Pathology, 2011Co-Authors: Remmi S. Singh, Helen H. WangAbstract:The “Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS)” category in the Bethesda System for Reporting Thyroid Cytology is heterogeneous and includes both specimens with borderline cellularity/compromised quality and those with genuine atypia. We have used a reporting scheme that is similar to the Bethesda System but does not include an AUS/FLUS category. We retrospectively reviewed all reports on thyroid FNA and thyroidectomy specimens submitted to the Beth Israel Deaconess Medical Center from January 2006 to December 2008. The positive predictive values for various categories and subcategories in this scheme demonstrate that the AUS/FLUS category can be eliminated to provide information for the most appropriate management of patients with thyroid nodules.
Remmi S. Singh - One of the best experts on this subject based on the ideXlab platform.
-
Reporting thyroid FNA before and after implementation of the Bethesda System—one institution's experience
Diagnostic Cytopathology, 2014Co-Authors: Kathriel J. Brister, Remmi S. Singh, Helen H. WangAbstract:Background The Bethesda System for Reporting Thyroid Cytopathology was published in 2008 and was implemented at Beth Israel Deaconess Medical Center (BIDMC) in June, 2010. Prior to this date, our diagnostic scheme was similar to the Bethesda System, except for the category of “Atypia/Follicular Lesion of Undetermined Significance” (AUS). This study evaluates the impact of the Bethesda System on the rate and the positive predictive value (PPV) of the diagnostic categories at BIDMC. Methods We performed a retrospective review of all thyroid fine-needle aspirations (FNAs) during the time periods January, 2006 to November, 2008 and June, 2010 to July, 2011 and the subsequent thyroidectomy specimens. Results Post-Bethesda System, diagnoses that are equivocal for diverse reasons and which have wide-ranging PPVs are now all grouped into the AUS category, and the proportion of cases that are in the atypical/AUS category rose from 3.7% in the pre-Bethesda period to 12% in the post-Bethesda period. Conclusion The AUS category has a PPV approaching 50% in our lab. This creates uncertainty regarding the appropriate management for this category and may cause unnecessary overuse of molecular testing for cases in the AUS category. Diagn. Cytopathol. 2015;43:28–31. © 2014 Wiley Periodicals, Inc.
-
eliminating the atypia of undetermined significance follicular lesion of undetermined significance category from the Bethesda System for reporting thyroid cytopathology
American Journal of Clinical Pathology, 2011Co-Authors: Remmi S. Singh, Helen H. WangAbstract:The “Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS)” category in the Bethesda System for Reporting Thyroid Cytology is heterogeneous and includes both specimens with borderline cellularity/compromised quality and those with genuine atypia. We have used a reporting scheme that is similar to the Bethesda System but does not include an AUS/FLUS category. We retrospectively reviewed all reports on thyroid FNA and thyroidectomy specimens submitted to the Beth Israel Deaconess Medical Center from January 2006 to December 2008. The positive predictive values for various categories and subcategories in this scheme demonstrate that the AUS/FLUS category can be eliminated to provide information for the most appropriate management of patients with thyroid nodules.
-
Eliminating the "Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance" category from the Bethesda System for Reporting Thyroid Cytopathology.
American Journal of Clinical Pathology, 2011Co-Authors: Remmi S. Singh, Helen H. WangAbstract:The “Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS)” category in the Bethesda System for Reporting Thyroid Cytology is heterogeneous and includes both specimens with borderline cellularity/compromised quality and those with genuine atypia. We have used a reporting scheme that is similar to the Bethesda System but does not include an AUS/FLUS category. We retrospectively reviewed all reports on thyroid FNA and thyroidectomy specimens submitted to the Beth Israel Deaconess Medical Center from January 2006 to December 2008. The positive predictive values for various categories and subcategories in this scheme demonstrate that the AUS/FLUS category can be eliminated to provide information for the most appropriate management of patients with thyroid nodules.
William C. Faquin - One of the best experts on this subject based on the ideXlab platform.
-
The role of thyroid fine needle aspiration cytology and the Bethesda System for reporting thyroid
2020Co-Authors: Massimo Bongiovanni, Edmund S Cibas, William C. FaquinAbstract:Thyroid fine needle aspiration (FNA) is among the most commonly performed non-gynaecologic cytologic procedures and the single most effective tool for guiding the initial management of a patient with a thyroid nodule. Its acceptance as a reliable preoperative test relies on its high sensitivity and specificity. The recently developed Bethesda System for Reporting Thyroid Cytopathology, has advanced the field by promoting a standard reporting terminology for thyroid aspirates. In addition, it allows communication with the referring physician to occur in terms that are unambiguous, reproducible, and clinically helpful.
-
Fine-Needle Aspiration of the Thyroid Gland: The 2017 Bethesda System
2020Co-Authors: William C. Faquin, Guido Fadda, Edmund S CibasAbstract:Abstract Fine-needle aspiration (FNA) is an essential test in the evaluation of a patient with a thyroid nodule. The result of the FNA determines, in large part, whether a patient can be followed clinically or referred for surgery. Guidelines have been established for selecting a nodule for aspiration. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has standardized the reporting of thyroid cytopathology and consists of the following six diagnostic categories: nondiagnostic, benign, atypia of undetermined significance/ follicular lesion of undetermined significance (AUS/FLUS), follicular neoplasm, suspicious for malignancy, and malignant.
-
the role of thyroid fine needle aspiration cytology and the Bethesda System for reporting thyroid cytopathology
Diagnostic Histopathology, 2011Co-Authors: Edmund S Cibas, Massimo Bongiovanni, William C. FaquinAbstract:Abstract Thyroid fine needle aspiration (FNA) is among the most commonly performed non-gynaecologic cytologic procedures and the single most effective tool for guiding the initial management of a patient with a thyroid nodule. Its acceptance as a reliable preoperative test relies on its high sensitivity and specificity. The recently developed Bethesda System for Reporting Thyroid Cytopathology, has advanced the field by promoting a standard reporting terminology for thyroid aspirates. In addition, it allows communication with the referring physician to occur in terms that are unambiguous, reproducible, and clinically helpful.
Zubair W Baloch - One of the best experts on this subject based on the ideXlab platform.
-
the Bethesda System for reporting thyroid cytology tbsrtc from look backs to look ahead
Diagnostic Cytopathology, 2020Co-Authors: Zubair W Baloch, Virginia A LivolsiAbstract:: The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was formalized in October 2007 by experts in thyroidology at the National Institute of Health in Bethesda, Maryland. The first edition of the TBSRTC book was published in 2010 and the second edition in 2018. The TBSRTC is widely employed in cytology practices in the United States and has also served as a model for similar tiered classification schemes for reporting thyroid cytopathology specimens. The tremendous success of TBSRTC cannot be underscored, it has provided a diagnostic framework which is well aligned with the present and the future of thyroid nodule management.
-
analysis of the Bethesda System for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes
Advances in Anatomic Pathology, 2012Co-Authors: Lawrence Q Wong, Zubair W BalochAbstract:The Bethesda System for Reporting Thyroid Cytopathology is a standardized reporting System for classifying thyroid fine-needle aspiration results comprising of 6 diagnostic categories with unique risks of malignancy and recommendations for clinical management. The majority of thyroid nodules are ben